Trial Profile
A single-centre prospective observational study of lumacaftor-ivacaftor in Phe508del homozygous patients with end-stage cystic fibrosis pulmonary disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2018
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2018 New trial record